|Day Low/High||65.43 / 66.26|
|52 Wk Low/High||55.06 / 68.12|
- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
The drug is responsible for more than 60% of AbbVie's top line.
Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.
Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.
- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics
Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.
Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.
Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.
Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.
U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.
Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.
Biotech investors should keep a close eye on the progress in this huge potential market.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
- New data demonstrated high SVR(12) rates across compensated cirrhotic patients with genotype 1, 2, 4, 5 or 6 chronic hepatitis C virus (HCV) infection with 12 weeks of treatment(1)
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.